小児がん向けCAR-T細胞療法の世界市場：2024年～2031年

概要

小児がん向けCAR-T細胞療法の世界市場は、2023年に18億米ドルに達し、2031年には115億米ドルに達すると予測され、予測期間2024-2031年のCAGRは27.3%で成長する見込みです。

キメラ抗原受容体（CAR）T細胞療法は、T細胞と呼ばれる免疫細胞を実験室で遺伝子工学的に変化させることで、がんと闘わせる方法です。

CAR-T細胞療法は、がん患者にとって非常に有望な新たな治療法であり、化学療法、外科手術、放射線療法よりも好まれるようになってきています。CAR-T細胞はがん細胞を検出し、闘うことができます。この治療法は、B細胞性急性リンパ芽球性白血病の小児患者やある種のリンパ腫の治療に使用されることが多くなっています。

市場力学：

促進要因と抑制要因

小児がん治療における調査・開発活動の活発化

研究開発の活発化により、革新的な工学的手法を用い、複数の抗原を標的とする次世代CAR-T治療が生み出されています。様々な小児がんに関する主要な開発により、治療の選択肢が増え、CAR-T療法の有効性が向上しています。

例えば、2022年5月28日、ノバルティスは米国食品医薬品局（FDA）より、2ライン以上の全身療法後の再発または難治性（r/r）の濾胞性リンパ腫（FL）患者の治療薬として、Kymriah（tisagenlecleucel）の早期承認を取得しました。Kymriahは現在、3つの適応症でFDAの承認を受けており、成人および小児の両方で承認された唯一のCAR-T細胞療法です。

さらに2023年4月、オートラス・セラピューティクスplcは、小児B細胞性急性リンパ芽球性白血病を対象としたAUTO1/22試験（CARPALL）のデータアップデートを、2023年の第49回欧州血液骨髄移植学会（EBMT）年次総会での口頭発表で発表しました。このように、革新的なアプローチが市場全体の成長を後押しする可能性があります。

CAR-T細胞療法の高額な治療費

CAR-T細胞療法は、患者1人当たり数十万米ドルを超える高額な治療費がかかるため、多くの患者が治療を受けることができないです。このため、救命の可能性のある治療を必要とする小児患者は、治療を受けることができないです。例えば、Kymriahの定価は47万5,000ドルで、治療の提供、入院、毒性管理、フォローアップに関連する費用は考慮されていないです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 小児がん治療における研究開発の活発化
  • 抑制要因
    • CAR-T細胞療法の高い治療費
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIオピニオン

第6章 がんタイプ別

• 急性リンパ芽球性白血病（ALL）
• 多発性骨髄腫
• 非ホジキンリンパ腫
• その他

第7章 エンドユーザー別

• 病院
• がんセンター
• 研究機関
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第10章 企業プロファイル

• Novartis AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Seattle Children's Hospital
• Autolus Therapeutics
• Baylor College of Medicine

第11章 付録

Overview

Global CAR-T Cell Therapy for Pediatric Cancers Market reached US$ 1.8 billion in 2023 and is expected to reach US$ 11.5 billion by 2031, growing at a CAGR of 27.3% during the forecast period 2024-2031.

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells to fight cancer by changing them genetically engineered in a laboratory.

CAR-T cell therapy is an incredibly promising emerging treatment for cancer patients and is increasingly being preferred over chemotherapy, surgery, and radiation. They can detect and fight cancer cells. This therapy is increasingly used to treat pediatric patients with B-cell acute lymphoblastic leukemia and in certain types of lymphoma.

Market Dynamics: Drivers & Restraints

Rising research and developmental activities in pediatric cancer treatment

Increasing research and development is generating next-generation CAR-T treatments, such as those that use innovative engineering methods and target several antigens. In concern with a variety of pediatric cancers, the major developments increase therapy options and improve the effectiveness of CAR-T therapies.

For instance, on May 28, 2022, Novartis the US Food and Drug Administration (FDA) granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. Kymriah is now FDA-approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings.

Additionally, in April 2023, Autolus Therapeutics plc announced a data update from the AUTO1/22 study (CARPALL) in Pediatric B-cell Acute Lymphoblastic Leukemia in an oral presentation at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in 2023. Thus, innovative approaches could help in driving the overall market growth.

High treatment costs of CAR-T cell therapy

Many patients cannot afford CAR-T cell therapy due to its expensive cost, which frequently exceeds several hundred thousand dollars per patient. This restricts pediatric patients who require potentially life-saving treatments from having access to them. For instance, Kymriah's list price is $475,000, not accounting for costs related to the delivery of care, inpatient hospitalization, toxicity management, or follow-up.

Segment Analysis

The global CAR-T cell therapy for pediatric cancers market is segmented based on cancer type, end-user, and region.

Acute Lymphoblastic Leukemia segment is expected to dominate the market share

Acute Lymphoblastic Leukemia (ALL) accounted for the major portion of the CAR-T cell therapy market. This is due to the increasing incidence of cancers. CAR T-cell therapy is approved for the treatment of children and adolescents with fairly advanced B-cell acute lymphoblastic leukemia (ALL). Because of the increasing incidence rate, more patients are benefiting from CAR-T therapy, which is boosting the segment growth.

For instance, according to the American Cancer Society in 2024, leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. About 3 out of 4 leukemias among children and teens are acute lymphocytic leukemia (ALL).

High rates of total recovery have been achieved with CAR-T treatments, especially those that target CD19 such as Kymriah, which have demonstrated remarkable success in treating relapsed or refractory B-cell ALL. Because of this achievement, CAR-T is now the suggested method of treatment for this group of patients. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the CAR-T cell therapy for pediatric cancers market share

North America accounts for the largest share of the global CAR-T Cell Therapy market. The region is expected to hold a significant portion of the market share owing to the rising incidence of cancer in the region, the increasing awareness among the public regarding treatment options, and the increasing research and development of new CAR-T cell therapies for children.

There is an increased risk of pediatric cancers in the US. Several sources are estimating a rapid increase in cancers among children. For instance, according to the About 9,620 children in the United States under the age of 15 will be diagnosed with cancer in 2024. After accidents, cancer is the second leading cause of death in children ages 1 to 14. About 1,040 children under the age of 15 are expected to die from cancer in 2024.

With the increasing number of cancers, there will be an increasing demand and need for the therapies. This is expected to drive the region's market growth and is expected to hold the major position in the market share.

Market Segmentation

By Cancer Type

• Acute Lymphoblastic Leukemia (ALL)
• Multiple Myeloma
• Non-Hodgkin Lymphoma
• Others

By End-User

• Hospitals
• Cancer Centers
• Research Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Novartis AG, Seattle Children's Hospital, Autolus Therapeutics, and Baylor College of Medicine among others.

Why Purchase the Report?

• To visualize the global CAR-T cell therapy for pediatric cancers market segmentation based on cancer type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of CAR-T cell therapy for pediatric cancers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global CAR-T cell therapy for pediatric cancers market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Cancer Type
• 3.2. Snippet by End-User
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Research and Developmental Activities in Pediatric Cancer Treatment
  • 4.1.2. Restraints
    • 4.1.2.1. High Treatment Costs of CAR-T Cell Therapy
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Cancer Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 6.1.2. Market Attractiveness Index, By Cancer Type
• 6.2. Acute Lymphoblastic Leukemia (ALL)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Multiple Myeloma
• 6.4. Non-Hodgkin Lymphoma
• 6.5. Others

7. By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Cancer Centers
• 7.4. Research Institutes
• 7.5. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
    • 8.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.3.1. The U.S.
    • 8.2.3.2. Canada
    • 8.2.3.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
    • 8.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.4.1. Germany
    • 8.3.4.2. UK
    • 8.3.4.3. France
    • 8.3.4.4. Italy
    • 8.3.4.5. Spain
    • 8.3.4.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
    • 8.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.4.1. Brazil
    • 8.4.4.2. Argentina
    • 8.4.4.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
    • 8.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.4.1. China
    • 8.5.4.2. India
    • 8.5.4.3. Japan
    • 8.5.4.4. South Korea
    • 8.5.4.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
    • 8.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
• 8.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Novartis AG *
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
• 10.2. Seattle Children's Hospital
• 10.3. Autolus Therapeutics
• 10.4. Baylor College of Medicine

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us